David J. Burkhart

1.2k total citations
50 papers, 930 citations indexed

About

David J. Burkhart is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, David J. Burkhart has authored 50 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 16 papers in Molecular Biology and 12 papers in Epidemiology. Recurrent topics in David J. Burkhart's work include Immune Response and Inflammation (14 papers), Immunotherapy and Immune Responses (12 papers) and Influenza Virus Research Studies (8 papers). David J. Burkhart is often cited by papers focused on Immune Response and Inflammation (14 papers), Immunotherapy and Immune Responses (12 papers) and Influenza Virus Research Studies (8 papers). David J. Burkhart collaborates with scholars based in United States, Canada and Italy. David J. Burkhart's co-authors include Johannes Stammel, Tad H. Koch, Jay T. Evans, Michael P. Coleman, Benjamin L. Barthel, Shannon M. Miller, Hélène G. Bazin, Hardeep S. Oberoi, Nicholas R. Natale and Brendan Twamley and has published in prestigious journals such as Nature Materials, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

David J. Burkhart

48 papers receiving 907 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David J. Burkhart United States 17 330 241 168 133 131 50 930
Byung‐Kwon Choi United States 20 724 2.2× 103 0.4× 59 0.4× 5 0.0× 126 1.0× 36 1.1k
Matthieu Montès France 27 870 2.6× 259 1.1× 20 0.1× 4 0.0× 261 2.0× 58 1.7k
M.V.B. Dias Brazil 19 599 1.8× 13 0.1× 18 0.1× 26 0.2× 154 1.2× 53 844
A. Seetharama Acharya United States 23 934 2.8× 57 0.2× 25 0.1× 2 0.0× 64 0.5× 86 1.6k
Pamela Greenwell United Kingdom 19 749 2.3× 229 1.0× 54 0.3× 1 0.0× 193 1.5× 66 1.2k
Ritu Jain India 17 270 0.8× 13 0.1× 54 0.3× 9 0.1× 21 0.2× 100 887
Mahmoud ElHefnawi Egypt 21 627 1.9× 78 0.3× 23 0.1× 137 1.0× 85 1.3k
Wilfred W. Li United States 14 630 1.9× 84 0.3× 70 0.4× 75 0.6× 27 1.0k
Muriel Jourdan France 18 768 2.3× 18 0.1× 26 0.2× 8 0.1× 118 0.9× 45 1.1k
Ying‐Ta Wu Taiwan 19 696 2.1× 188 0.8× 17 0.1× 397 3.0× 43 1.4k

Countries citing papers authored by David J. Burkhart

Since Specialization
Citations

This map shows the geographic impact of David J. Burkhart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Burkhart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Burkhart more than expected).

Fields of papers citing papers by David J. Burkhart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Burkhart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Burkhart. The network helps show where David J. Burkhart may publish in the future.

Co-authorship network of co-authors of David J. Burkhart

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Burkhart. A scholar is included among the top collaborators of David J. Burkhart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Burkhart. David J. Burkhart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Le, Nguyet‐Minh Nguyen, Hardik Amin, Linda D. Hicks, et al.. (2025). A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity. Journal of Controlled Release. 384. 113901–113901. 2 indexed citations
2.
Riel, Asia Marie S., Linda D. Hicks, Walid Abdelwahab, et al.. (2024). Systematic Evaluation of Regiochemistry and Lipidation of Aryl Trehalose Mincle Agonists. International Journal of Molecular Sciences. 25(18). 10031–10031. 1 indexed citations
4.
Miller, Shannon M., Linda D. Hicks, Hardik Amin, et al.. (2023). A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. npj Vaccines. 8(1). 97–97. 12 indexed citations
5.
Massena, Casey J., Linda D. Hicks, Jay T. Evans, et al.. (2023). Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge. Bioconjugate Chemistry. 34(10). 1811–1821. 12 indexed citations
6.
Amin, Hardik, et al.. (2023). Deciphering immunological mechanisms underlying the efficacy of nanoparticle-based vaccines against opioid use disorder (OUD). The Journal of Immunology. 210(Supplement_1). 71.20–71.20. 1 indexed citations
7.
Abdelwahab, Walid, et al.. (2020). Co-adsorption of synthetic Mincle agonists and antigen to silica nanoparticles for enhanced vaccine activity: A formulation approach to co-delivery. International Journal of Pharmaceutics. 593. 120119–120119. 10 indexed citations
9.
Miller, Shannon M., et al.. (2018). Investigation of novel TLR7/8 ligands in combination with TLR4 ligands as adjuvants to drive cell mediated anti-influenza immunity. The Journal of Immunology. 200(Supplement_1). 125.16–125.16. 3 indexed citations
10.
Araujo, Alessandra, David J. Burkhart, Lucas J. Kirschman, et al.. (2015). Writing Your Way into High Impact Factor Journals. Bulletin of the Ecological Society of America. 96(2). 312–316.
12.
Hallé, Maxime, Jonathan Boulais, Julien R. St-Jean, et al.. (2015). Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. Journal of Immunological Methods. 424. 64–79. 18 indexed citations
13.
Natale, Nicholas R., et al.. (2010). Preparation of chiral isoxazole carbinols via catalytic asymmetric Corey-Bakshi-Shibata reduction.. ARKIVOC. 2010(8). 97–107. 5 indexed citations
14.
Patel, Sarjubhai A., Trideep Rajale, Erin M. O’Brien, et al.. (2009). Isoxazole analogues bind the System xc- transporter: Structure–activity relationship and pharmacophore model. Bioorganic & Medicinal Chemistry. 18(1). 202–213. 28 indexed citations
15.
Koch, Tad H., et al.. (2007). Anthracycline–Formaldehyde Conjugates and Their Targeted Prodrugs. Topics in current chemistry. 283. 141–170. 14 indexed citations
16.
Stammel, Johannes, et al.. (2006). Search-based determination of refactorings for improving the class structure of object-oriented systems. 1909–1916. 178 indexed citations
17.
Burkhart, David J., et al.. (2005). Isoxazole Ionotropic Glutamate Neurotransmitters. Current Medicinal Chemistry. 12(5). 617–627. 1 indexed citations
18.
Natale, Nicholas R., et al.. (2003). Preparation of Keto-Isoxazole Polyketide Synthons. Synlett. 2213–2215. 1 indexed citations
19.
Burkhart, David J., et al.. (2001). An improved procedure for the lateral lithiation of ethyl 4-acetyl-5-methyl-3-isoxazolyl carboxylate. Tetrahedron. 57(38). 8039–8046. 10 indexed citations
20.
Burkhart, David J., Ashwani Vij, & Nicholas R. Natale. (1999). The structure-based design of novel AMPA bioisosteres. Journal of Chemical Crystallography. 29(7). 749–758. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026